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Adeno-associated virus (AAV) vectors have become an important tool for delivering therapeutic genes for
a wide range of neurological diseases. AAV serotypes possess differential cellular tropism in the central
nervous system. Although several AAV serotypes or mutants have been reported to transduce the brain
efficiently, conflicting data occur across studies with the use of various rodent strains from different
genetic backgrounds. Herein, we performed a systematic comparison of the brain transduction properties
among five AAV serotypes (AAV2, 5, 7, 8, and 9) in two common rodent strains (C57BL/6J and FVB/N),
following local intrastriatal injection of AAV vectors encoding enhanced green fluorescent protein (EGFP)
driven by the CBh promoter. Important differences were found regarding overall cellular tropism and
transduction efficiency, including contralateral transduction among the AAV serotypes and between the
mouse strains. We have further found loss of NeuN-immunoreactivity and microglial activation from AAV
transduction in the different mouse strains. The important strain-specific differences from our study
suggest that the genetic background of the mouse may affect AAV serotype transduction properties in the
brain. These data can provide valuable information about how to choose an effective AAV vector for
clinical application and interpret the data obtained from preclinical studies and clinical trials.
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INTRODUCTION
ADENO-ASSOCIATED VIRUS (AAV) has emerged as an
important vector candidate for delivering targeting
sequences for a broad range of neurodegenerative
diseases, including Parkinson’s disease, Hunting-
ton’s disease, and Alzheimer’s disease.1–3 AAV has
13 serotypes, more than 100 naturally occurring
variants, and an expanding library of modified
capsids, which can be used as gene delivery vehi-
cles. However, selecting an appropriate capsid
from the array of AAV serotypes/variants can be
difficult since different AAV capsids have a variety
of tissue transduction abilities, which only par-
tially result from the interaction with different
receptors or coreceptors on the targeted cells.4–6
While AAV vectors have been effectively used to
target several different cell types, including retinal
pigmented epithelial cells and hepatocytes, exten-
sive effort has also been put toward identifying
specific AAV capsids with different phenotypes for
targeting various cell types in the brain. However,
conflicting results regarding cell targeting effi-
ciency in the brain have been reported in studies
using mouse models. This may be due to utilization
of a variety of different rodent strains among the
different studies.7–10 Furthermore, the remark-
able brain transduction of an AAV9 variant named
PHP.B following intravenous infusion was subse-
quently found to be limited to mice from a C57BL/
6J background.11 PHP.B does not show enhanced
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transduction in BALB/cJ mice or nonhuman pri-
mates, which has been linked to different Ly6a
haplotypes, at least between mouse species.12 In ad-
dition, genetic variations among multiple strains
established by the Collaborative Cross were identi-
fied to contribute to the differential transduction
by lentiviral vector-delivered luciferase.13 Given
the current literature, it is apparent that a sys-
tematic characterization of the transduction
properties of AAV serotypes in the central ner-
vous system of multiple rodent strains remains
critically unaddressed.
Recently, gene therapy has shown gains in
overall success and promising results in clinical
trials for a wide range of genetic diseases; however,
significant variations have always existed in the
efficacy and safety measured among treated pa-
tients within each clinical study.14–16 Further-
more, the various responses in individual patients,
especially certain immunological effects, were not
predicted by the preclinical studies.16 The use of
single animal strains in preclinical studies may
have led to an underestimation of the variability in
efficacy and safety.
Here, we studied the impact of the host genetic
background on AAV transduction properties with
different AAV serotypes in different mouse strains.
Two common laboratory mouse strains, C57BL/6J
and FVB/N, were transduced with several popular
AAV serotypes (AAV2, 5, 7, 8, and 9). We chose
these serotypes due to their historical precedent
(AAV2), their popular use in the brain (AAV9),
and observations from our laboratory of robust
brain transduction with serotypes 5, 7, and 8. The
C57BL/6J mouse strain is the most widely used
inbred strain in preclinical research. Furthermore,
this strain contains a permissive background for
maximal expression of most mutations and is
commonly used in the production of transgenic
mice. FVB inbred mice are also ideal for generating
transgenic mouse models, such as the YAC128
strain, which was developed to study Huntington’s
disease, because these mice have prominent pro-
nuclei that enable more efficient transgene micro-
injection and high reproductive performance 17;
hence, both mouse strains are relevant to current
preclinical gene therapy studies. We found that
different AAV capsids possess differential trans-
duction properties and that the host genetic back-
ground strongly affects the ability of AAV vectors
to transduce brain tissue after intrastriatal injec-
tion. Our data suggest that the strain-specific
differences in AAV vector-medicated brain trans-
duction may contribute to the variable results ob-
served in individual clinical patients following
gene therapy. This study also highlights the im-
portance of identifying specific genetic factors that
could impact AAV brain transduction.
RESULTS
Comparison of brain enhanced green
fluorescent protein (EGFP) expression
in the striatum conferred by different
AAV serotypes in two strains of mice
We analyzed transgene enhanced green fluor-
escent protein (EGFP) expression in the brain, 5
weeks after intrastriatal injection with AAV2, 5, 7, 8,
and 9 in C57BL/6and FVB mice. As shown in Fig. 1A,
all serotypes are capable of transducing brain tissue
efficiently in both strains of mice. However, for C57,
three serotypes AAV5, AAV7, and AAV9 transduced
a relatively larger area than serotypes AAV2 and
AAV8, and also resulted in a higher fluorescence
index (Fig. 1A–C). The fluorescence index indicates
the total EGFP fluorescence, including both the
number of pixels with positive GFP expression and
the levels of GFP signal in each pixel. In C57 mice,
AAV5 is the most widespread virus (Fig. 1C), but has
less or similar total EGFP expression in transduced
cells as AAV7 or AAV9 (Fig. 1B). In contrast, the FVB
mice did not display a significant difference in total
EGFP expression among the five AAV serotypes,
although AAV5 transduced a significantly larger
area (Fig. 1A–C). When comparing between the two
species of mice, AAV7 produced significantly more
EGFP in C57 mice compared with EGFP in FVB mice
(analysis of variance [ANOVA]; p < 0.05, Fig. 1B). In
general, FVB mice did not show significant differ-
ences between the serotypes with regard to fluo-
rescent index, whereas C57s showed significant
differences between serotypes, with AAV5, AAV7,
and AAV9 being the highest (Fig. 1B). There were
significant differences between the serotypes when
looking at the spread of transduction, with AAVs 5,
7, and 9 being the highest in both mouse strains,
although only significantly so in C57s (Fig. 1C).
Ipsilateral and contralateral cortex EGFP
expression
As the striatum receives axonal innervation from
both the ipsilateral and contralateral cortices
through corticostriatal projections, retrograde axo-
nal transport after striatal AAV injection could re-
sult in EGFP expression in cortical neurons in both
injected and noninjected hemispheres. In our study,
we found cortical neuron EGFP expression in most
of the AAV-injected mice, although to varying de-
grees (Fig. 2A, B). In general, the cortex in C57 mice
had stronger EGFP signal on both sides of the brain
than in FVB mice (Fig. 2C). EGFP expression from
AAV7 in the ipsilateral cortex is significantly higher
in C57 mice than all other serotypes in both strains
of mice examined ( p < 0.05, Fig. 2C). On the con-
tralateral side, AAV5 resulted in significantly more
cortical neurons expressing EGFP in C57 mice than
in FVB mice ( p < 0.001, Fig. 2D). AAV5 also exceeds
all other serotypes in cortical EGFP expression in
both C57 and FVB mice on both sides of the cortex,
but particularly on the contralateral side, which
may indicate a pronounced ability of AAV5 to infect
axon termini (Fig. 2D). The quantification of retro-
grade trafficking events is complicated by EGFP
expression arising from anterograde trafficking (or
diffusion) of EGFP protein from neurons on the ip-
silateral side that have axonal projections into the
contralateral side. Since we measured total EGFP
signal and diffusion volume, and did not count in-
dividual cell bodies, we were unable to distinguish
between these two possibilities.
Cellular tropism of AAV vectors
in C57 and FVB mice
AAV capsids have different cellular tropisms
driven, in part, by differences in receptor binding.
Since the brain comprised of a collection of differ-
ent cell types, including various neurons and glial
cells, we sought to identify cell-type differences in
transduction between AAV serotypes and mouse
strains. At 5 weeks postinjection, we removed, sec-
tioned, and stained the brains of the mice injected
with EGFP AAV vectors. By using the cell-type-
specific markers NeuN (neuronal marker), GFAP
(astrocyte marker), and olig-2 (oligodendrocyte
marker), we were able to determine the cell-specific
tropism of AAV serotypes 2, 5, 7, 8, and 9 in C57
and FVB mice. Three sections (each 40 lm thick),
which represented the central concentration of EGFP
expression, were chosen per animal for quantifi-
cation of colocalization with the cell-type-specific
markers. We also found a lack of immunoreactivity
of NeuN, which occurred using specific serotypes in
both mouse strains. With the exception of those
cells that had a loss of NeuN immunoreactivity,
there is a higher percentage of transduction in
neurons (40–60% of all EGFP transduced cells)
when compared with transduction of astrocytes
and oligodendrocytes (Fig. 3D–F). We excluded the
animals that displayed a loss of NeuN immunore-
Figure 1. Transduction efficiency of AAV2, 5, 7, 8, and 9 in brains of C57BL/6 and FVB mice 5 weeks following AAV injection. (A) Representative confocal
fluorescence images of caudate putamen (CPu) in C57BL/6 (Top) or FVB (Bottom) mice injected with various AAV serotypes (objective 2 · ; scale bar is 500 lm).
Green: EGFP expression. Blue: DAPI staining. (B) Fluorescence index analysis of EGFP expression conferred by AAV stereotypes in C57 and FVB mice. (C)
Quantity analysis of AAV serotype transduction by diffusion volume (um3) in C57 and FVB mice. All bars represent mean – SEM. n = 4–5 in each group. *p < 0.05,
**p < 0.01, ***p < 0.001 compared within C57 or FVB group. &p < 0.05 compared between C57 and FVB with AAV7 injection. AAV, adeno-associated virus; DAPI,
4¢,6-diamidino-2-phenylindole; EGFP, enhanced green fluorescent protein; SEM, standard error of the mean.
activity in quantification of NeuN-positive cell co-
localization, and found that AAV8 demonstrates
less neuronal preference than AAV9 in C57 mice
(*p < 0.05, Fig. 3D). In FVB mice, a loss of NeuN
immunoreactivity could be seen with the AAV se-
rotypes tested except for AAV8, in which 60% of
the EGFP-positive cells are neurons Fig. 3D). The
transduction in astrocytes varied from *3% to 4%
with AAV9 to 14–19% with AAV5 in both strains
(Fig. 3E). There is significantly more astrocyte
transduction with AAV5 than with AAV7 and
AAV9 in FVB mice (**p < 0.01 or *p < 0.05, Fig. 3E).
Notably, each AAV serotype exhibited a similar
amount of transduction in astrocytes in both C57
mice and FVB mice (Fig. 3E). AAV8 transduction
resulted in *23% of oligodendrocytes that were
EGFP positive in C57 mice, which is significantly
more ( p < 0.001; Fig. 3F) than that measured in
FVB mice (only 4.4%). In C57 mice, AAV7 also
showed a high percentage of oligodendrocyte
transduction, similar to AAV8. In contrast, in FVB
mice, AAV7 transduced significantly more oligo-
dendrocytes than AAV8 (*p < 0.05; Fig. 3F). AAV8
displays the largest difference in oligodendro-
cyte transduction between the two strains of mice
(Fig. 3F).
NeuN loss and rotarod behavioral
testing results
In the course of determining neuronal cell tro-
pism for the AAV serotypes, we found that the area
of AAV transduction frequently also displayed a
lack of NeuN staining that was not observed in
uninjected or untransduced areas of the brain. This
loss of NeuN immunostaining had both mouse
strain- and serotype-specific differences, with the
Figure 2. EGFP expression in ipsilateral (Ipsi) and contralateral (CL) cortex 5 weeks post-AAV vector injection in striatum. (A, B) Representative confocal
images (objective 20 · ; scale bar is 200 lm) from both sides in C57 (A) and FVB (B) mice injected with various AAV serotypes. (C, D) Quantitative analysis of
fluorescent index of the cortex EGFP expression from ipsilateral cortex (C) and contralateral cortex (D) in C57 and FVB mice. All bars represent mean – SEM.
n = 3 in each group. *p < 0.05; **p < 0.01; ***p < 0.001 compared within C57 or FVB group. &p < 0.05; &&&p < 0.001 compared between C57 and FVB with AAV7
injection.
loss occurring more frequently in the FVB strain
(Fig. 5A, B). Loss of NeuN is most prominent with
AAV5 and AAV7 transduction in FVB mice, in
which the whole striatum and adjacent cortex had
extensive loss of NeuN immunoreactivity (Fig. 4A,
C, F). Quantification of NeuN-positive cells in the
ipsilateral half hemisphere, showed that AAV5-
and AAV7-injected FVB mice had the least number
of NeuN-positive cells (Fig. 5A), which also resul-
ted in the smallest area with intact NeuN-positive
signal (Fig. 5B). However, AAV5-EGFP did not
induce any NeuN loss in C57 mice, although we did
observe NeuN loss in one C57 mouse injected with
AAV7-EGFP (Fig. 4B). Significant strain differ-
ences were found in NeuN immunoreactivity with
the serotypes AAV5, AAV7, and AAV9. A portion
of AAV9-injected FVB mice also had a small area
of NeuN loss (Fig. 4D), however, this loss was not
observed in C57 mice. Most of the AAV2-injected
mice in both strains had a small region of NeuN
loss in the center of the viral EGFP expression site
(Fig. 4A, B). Interestingly, NeuN immunoreactiv-
ity remained intact in AAV8-injected mice in both
strains (Figs. 4E and 5A, B).
To evaluate if the loss of NeuN immunoreac-
tivity could result in compromised animal be-
havior, we injected FVB mice with AAV7-GFP
vectors as in the above serotype comparison
study. These mice were then subjected to a rotarod
test since motor deficits are the major symptoms if
striatal neurons are lost or functionally damaged,
as shown in Huntington’s disease.18 However, we
Figure 3. Cellular tropism of AAV2, 5, 7, 8, and 9 in C57 and FVB mice. The representative confocal images (objective 30 · ; scale bar is 50 lm) display the
serotypes that have the most transduction in a specific cell type in either C57 or FVB mice. (A) EGFP colocalization with neuron marker NeuN; (B) EGFP
colocalization with astrocyte marker GFAP; and (C) EGFP colocalization with oligodendrocyte marker Olig-2. The specific cell percentage is quantified by the
percentage of the number of a specific marker-positive cell in total EGFP-positive cells. (D–F) Cell percentage quantifications for neurons, astrocytes, and
oligodendrocytes. All bars represent mean – SEM. n = 3 in each group. *p < 0.05; **p < 0.01; ***p < 0.001 compared within C57 or FVB group. &&&p < 0.001
compared between C57 and FVB with AAV7 injection.
did not observe any significant reduction of mo-
tor performance in an accelerated rotarod test
for AAV7-injected FVB mice, compared with nor-
mal untreated FVB mice (Fig. 5C). The AAV7-
injected animals used for the behavioral study
had a similar NeuN-positive cell density and sim-
ilar NeuN loss area compared with AAV7-injected
FVB mice in the serotype comparison study
(Fig. 5D, E), which was significantly lower than
untreated mice.
Medium spiny neuron transduction
with AAVs-EGFP
The medium spiny neurons (MSNs) are the
major type of neurons in the striatum and are fre-
quently perturbed in Huntington’s disease.18 Thus,
we wanted to know if NeuN immunoreactivity
loss could affect MSNs. As a marker for MSNs,
we performed immunostaining for DARPP-32 and
we found that in AAV5- or AAV7-injected FVB
mice, which exhibited the most NeuN loss, DARPP-
32 immunoreactivity was also strongly reduced,
and significantly fewer neurons were found to be
positive for DARPP-32 staining overall (Fig. 6A;
AAV7 data not shown). However, we could still
observe normal neuron morphology from the
EGFP signal, suggesting that while those neurons
may lose NeuN and DARPP-32 immunoreactiv-
ity, they are still morphologically intact and able
to express GFP. In contrast to that, in AAV9- or
AAV2-injected FVB mice, we can find that some
DARPP-32-positive neurons colocalize with EGFP
expressing cells, but these neurons lack NeuN
staining (Fig. 6B; AAV2 data not shown). In this
situation, we speculate that the MSNs in the
striatum were less affected by the injection of
AAV2 or AAV9, since DARPP-32 immunoreactivity
remained intact. AAV8-injected FVB mice, as
well as the other animals without NeuN loss, show
normal NeuN and DARPP-32 immunostaining
patterns, which colocalize with EGFP expressing
neurons (Fig. 6C).
Figure 4. Loss of NeuN immunoreactivity in the ipsilateral striatum with injection of AAV-delivered EGFP. (A, B) Representative tiling confocal images
showing either loss of NeuN immunofluorescence (the region of loss is circled), or NeuN immunofluorescence remained intact postinjection. Images of NeuN
staining in normal untreated FVB or C57 mice also shown as control (20 · ; scale bar is 200 lm). (C–F) Higher magnification images (30 · ; scale bar is 15 lm)
showing intact NeuN or loss of NeuN and corresponding EGFP expression for individual neurons in the striatum.
Activation of microglia
Microglia are the primary innate immune cells
in the central nervous system (CNS) and microglia-
mediated immune responses play an important
role in the pathway leading to neuronal degenera-
tion and death.19,20 Therefore, it was important to
determine if microglia became activated in the
AAV-EGFP-injected mice. To measure this activa-
tion level, we immunostained 40 lm sections of
brain tissue with an antibody against Iba-1, which
is a marker for microglia that becomes upregulated
upon microglial activation (Fig. 7A–D). Quantifi-
cation of the microglial fluorescence index in both
ipsilateral and contralateral sides of the striatum
was performed (Fig. 7E). The results showed that
AAV5 and AAV7 induced a significant increase in
the amount of Iba-1 expression, compared with the
signal from the corresponding contralateral side of
the same striatum (Fig. 7E). Representative con-
focal images showed a difference between AAV7-
injected FVB and C57 mice (Fig. 7A–D). Note that
although FVB mice did not have as much GFP ex-
pression in the injected striatum compared with
the C57 mice, they do show significantly more
levels of microglial activation (Fig. 7B, D). Due to a
significantly low EGFP expression on the contra-
lateral side of the striatum, we were able to use this
region as an internal control to the ipsilateral side.
In addition, we did not observe a significant dif-
ference in microglial signal in the contralateral
side of the striatum in all of the mice.
DISCUSSION
We compared and analyzed the transduction
properties of five widely used recombinant AAV
(rAAV) vectors in two different strains of mice post
intra-striatal injection. Extensive studies have
been conducted for comparison of brain transduc-
tion efficiency and cellular tropism after intrace-
rebral administration of AAV vectors and the
results have been conflicting and complicated by
utilization of varied animal strains. For instance,
AAV8 was found to target only neurons in some
Figure 5. Quantitative analysis of NeuN immunoreactivity in ipsilateral striatum postinjection of varied AAV serotype-delivered EGFP. AAV7 and control FVB
mice were subjected to behavioral study 5 weeks postinjection, and rotarod performance, as well as NeuN-positive cell density, and intact NeuN area were
quantified to verify the consistency with a serotype comparison study. (A) Quantification of NeuN-positive cell density in ipsilateral half hemisphere. (B) Area
percentage from intact NeuN immunofluorescence in ipsilateral half hemisphere. (C) Latency time in accelerating rotarod test in AAV7-EGFP-injected and
nontreated control FVB mice. (D, E) NeuN-positive cell density (D) and intact NeuN area percentage (E) in ipsilateral half hemisphere in behavior study
animal. All bars represent mean – SEM. n = 4–5 in each group for (A, B), n = 11 (AAV7) and n = 6 (control) for (C), and n = 8 (AAV7) and n = 6 (control) for (D,
E). *p < 0.05; **p < 0.01; ***p < 0.001 compared within C57 or FVB group. &p < 0.05; &&&p < 0.001 compared between C57 and FVB mice.
studies, but have preference for astrocytes over
neurons in other studies.7–10 The conflicting data
has also occurred with other serotypes including
AAV2, 5 and 9.7,8,10 Therefore, it is important for
variables to be constrained so that different AAV
serotypes can be compared systematically. To our
understanding, this is the first time that multiple
rAAV vectors have been comprehensively com-
pared simultaneously in two mouse strains. In our
study, the five serotypes being tested can transduce
a variety of different cell types in the brain. In
general, AAV5 has more preference for targeting
GFAP-positive astrocytes, which comprises 20% of
all EGFP-positive cells, especially in the case of
FVB mice. However, there is no significant differ-
ence in targeting of astrocytes between the two
strains for each specific AAV serotype. Oligoden-
drocytes are the myelin-forming cells of the CNS.21
Our data showed that AAV8 and AAV7 transduced
oligodendrocytes most efficiently in C57 mice with
a transduction rate of 20% of total EGFP-positive
cells. However, in FVB mice, AAV7 retained a high
ability to transduce oligodendrocytes, but AAV8
had a diminished ability to target oligodendro-
cytes. For neuronal staining, the loss of NeuN im-
munoreactivity in several serotypes complicated
the quantification of colocalization between NeuN-
and EGFP-positive cells. In mice exhibiting normal
NeuN-staining, the majority of the EGFP signal
was expressed in NeuN-positive neurons, although
AAV8 had less neuron targeting specificity in C57
mice, which is consistent with the result that AAV8
targeted more oligodendrocytes in C57 mice. In
regards to the comparison of transduction effi-
ciency, a large discrepancy has also been reported
across multiple studies.7,8,22,23 In this study, we
found that in general, AAV5, 7 and 9 transduced
the most brain tissue and have higher intracellular
EGFP-expression than AAV2 and AAV8, for which
the viral diffusion and EGFP-expression is more
restricted. The widespread transduction of AAV5 is
consistent with several other serotype comparison
studies.7,10 Notably, when comparing the different
serotypes, even though AAV5 has the largest area
of transduction, it does not result in the strongest
intracellular EGFP-expression. Instead, AAV9 and
7 have higher intracellular EGFP-expression in
both mouse strains.
As the major neuronal cell type in the striatum,
MSNs receive input from the cortex, thalamus, and
brain stem, and the cortical fibers project to the
dendritic spines to form asymmetric terminals.24,25
In this study, we observed that neuron soma on
both sides of the cortex were labeled with EGFP.
While the neurons in the ipsilateral side of the
cortex were transduced by infection events near
Figure 6. The varied levels of potential neuronal toxicity to medium spiny neurons in striatum after AAV-EGFP administration suggested by different NeuN and
DARPP-32 immunoreactivity in FVB mice. (A) Loss of both NeuN and DARPP-32 immunofluorescence in AAV5-EGFP-injected FVB mice. (B) Loss of NeuN, but
DARPP-32 signal remained intact, in AAV9-EGFP-injected FVB mice. (C) In AAV8-EGFP-injected FVB mice, both NeuN and DARPP-32 remained intact. Images
were taken with 20 · objective, scale bar is 50 lm.
the site of injection, the neurons with cell bodies
residing on the contralateral side were likely trans-
duced by striatal-cortical retrograde transport of
AAV particles from infection events on the ipsilat-
eral side. AAV5 was able to abundantly label neu-
rons on both the ipsilateral and contralateral sides
in both strains, suggesting a strong retrograde
transport ability of AAV5, but again, this is com-
plicated by neurons projecting from the ipsilateral
side and maybe be only reflective of the ability of
AAV5 to effectively transduce neurons, in general.
Although, retrograde trafficking of AAV5 particles
has been previously reported.7 From the current
study, we see significantly less contralateral EGFP
expression in FVB mice for AAV5, even though it
has a similar amount of striatal transduction as
in C57 mice. The interpretation of this might be
associated with an increased vulnerability of neu-
rons in FVB mice in response to transgene ex-
pression following AAV transduction.
NeuN is an exclusively neuronal marker, and
anti-NeuN antibodies are able to identify most
types of neurons in the whole nervous system, with
the exception of several cell types in the brain.26
Several factors may lead to the lack of NeuN im-
munoreactivity, including neuronal injury post-
hypoxia and brain injury.27–30 On the other hand,
the abnormal synthesis of the NeuN protein or loss
of NeuN protein antigenicity due to the lack of
phosphorylation of the antibody binding sites can
also result in a lack of NeuN immunoreactivity.31,32
Our study shows that FVB mice are more vul-
nerable to the loss of NeuN immunoreactivity as-
sociated with EGFP-delivered by AAV vectors,
compared to C57 mice. There was extensive NeuN
immunoreactivity loss in the striatum of AAV5 and
AAV7-injected FVB mice. Additionally, AAV2 and
AAV9 delivered EGFP induced partial NeuN loss
in the striatum of FVB mice. We speculate that
the striatal neurons in FVB mice may be more
sensitive to the stress of foreign protein (EGFP)
overexpression. However, AAV8 was an exception
to this observation regarding NeuN loss since it
robustly transduced neurons in FVB mice but did
Figure 7. Differentiated microglial activation in ipsilateral and contralateral striatum with varied AAV-EGFP injection. Representative confocal images show
the difference in Iba-1 immunostaining between FVB and C57 mice in contralateral (CL) and ipsilateral (Ipsi) sides. (A) Contralateral striatum and (B) ipsilateral
striatum postinjection of AAV7-EGFP in FVB mice. (C) Contralateral striatum and (D) ipsilateral striatum postinjection of AAV7-EGFP in C57 mice. For each
(A–D), the left image is a layered image of both DAPI and EGFP. The middle image is Iba-1, and the right image is the zoom in image of boxed region in the
middle image. The image was taken with objective 20 · , scale bar is 250 lm. (E) Quantification of fluorescence index of microglial level on both sides for all
serotypes in C57 and FVB mice. All bars represent mean – SEM. n = 3 in each group. *p < 0.05; ***p < 0.001 compared between contralateral and ipsilateral
striatum in FVB mice with AAV5 and AAV7-EGFP injection.
not induce the NeuN loss seen with other sero-
types. Similar to our results, Watakabe’s study has
shown a loss of NeuN-positive cortical neurons of
marmosets following the injection of CMV-driven
AAV1 and AAV9-GFP.33 Some studies have sug-
gested a potential link of neuronal or glial toxicity
with AAV-carrying transgene expression, such as
GFP, both in vivo and in vitro.9,34,35 However, loss
of NeuN immunoreactivity is not necessarily neu-
ron loss and further study needs to be done to fig-
ure out the mechanisms behind the loss of NeuN
immunoreactivity in this study. It is interesting
that AAV2 transduced a similar amount of total
brain tissue as AAV8, but still caused a small area
of NeuN loss in both strains that was not observed
with AAV8. Also, the strain-specific difference
with NeuN immunoreactivity did not occur with
AAV2 and AAV8. This might be associated with the
interaction between AAV capsid and host tissue
genetic environment.
DARPP-32 is a dopamine- and cAMP-regulated
phosphoprotein, and is a major marker for MSNs in
the striatum.36 Our results indicated that in most
of the AAV5- and AAV7- (data not shown) injected
FVB mice, the region of NeuN loss also had a par-
tial loss of DARPP-32 immunoreactivity, although
EGFP-positive neurons still can be visualized with
intact cell morphologies. In contrast to that, in
AAV9- and AAV2- (data not shown) injected mice,
the DARPP-32 immunoreactivity was intact in the
region of NeuN loss, and some of the DARPP-32-
postive signal actually colocalized with EGFP-
positive cells. This demonstrates that AAV9 and
AAV2 might only induce a partial or mild DARPP-
32 dysfunction as compared to AAV5 and AAV7. A
severe compromise of the function of striatal MSNs
can cause motor coordination deficits.37,38 How-
ever, there is no significant decline in motor per-
formance as shown in our accelerating rotarod
testing39 with AAV7-CBh-EGFP injection, even
though this group of animals also demonstrated a
similar level of NeuN immunoreactivity loss as
AAV7 injected mice in the serotype comparison
study. The behavior data suggested that the loss of
NeuN as well as partial loss of DARPP-32 immu-
noreactivity in FVB mice has not compromised the
major function of MSNs in the striatum following
AAV5 and AAV7 injection.
Microglia are the primary resident immune cells
in the CNS and are usually the first to be activated
in response to tissue damage or brain infection.40
The beneficial or detrimental role of microglial
activation in neurological disorders remains to be
elucidated; however, microglial activation is the
major contributor to neuroinflammation in the
CNS.41 It is already known that neuroinflamma-
tion causes neurodegeneration in neurodegenera-
tive diseases, including striatal dopaminergic
degeneration in Parkinson’s disease.42 Our study
has suggested a significant upregulation of micro-
glial activation in the ipsilateral striatum of FVB
mice following AAV5 and AAV7 injection, which is
consistent with the significant lack of NeuN as well
as DARPP-32 immunoreactivity observed in those
mice. Therefore, it is reasonable for us to speculate
that the loss of NeuN and DARPP-32 immuno-
reactivity may result from neuroinflammation
caused by microglial activation. Whether other
cells, such as T helper cells, have infiltrated into
the brain and are involved in playing roles in the
process of AAV-mediated NeuN and DARPP-32
loss still requires further study.
Again, the genetic background plays an impor-
tant role in regulating the microglial activation
and therefore in differentiating the transduction
properties for AAV vectors in the brain. In Alzhei-
mer’s research, APP processing and beta-amyloid
levels were regulated according to various ge-
netic backgrounds43 and our results confirmed that
C57Bl/6J mice have reduced microglial activity
compared with mice with the FVB/N genetic
background after injection with AAV vectors.44
In this study, we compared five commonly used
AAV serotypes with regard to each serotype’s brain
transduction properties within the same strain,
but most importantly, we differentiate the trans-
duction of specific AAV serotypes between two
different genomic backgrounds. The results of this
study are summarized in Table 1, excluding the
cell-specific transduction profiles, highlighting the
differences we observed between the two strains
of mice. These results suggest that we should use
Table 1. Summary of serotype differences between the two
strains of mice
AAV2 AAV5 AAV7 AAV8 AAV9
Total EGFP C57 + +++ +++ + +++
FVB + ++ ++ ++ ++
Spread volume C57 + +++ +++ + ++
FVB + +++ ++ + ++
Contralateral transduction C57 + +++ ++ + ++
FVB + ++ + + +
Loss of NeuN C57 + - -/+ - -
FVB + +++ +++ - ++
Microglial Ipsi/CL C57 + - + - -
FVB +/- +++ +++ - ++
Total EGFP, spread volume, contralateral transduction, loss of NeuN
immunoreactivity, and microglial activation, indicated by relative Iba-1
ipsilateral to contralateral for each serotype in C57 and FVB mice, are
summarized by using simple indicators from the lowest value in a group (+)
to highest value in a group (+++).
AAV, adeno-associated virus; EGFP, enhanced green fluorescent protein;
Ipsi/CL, ipsilateral/contralateral.
caution when evaluating an AAV vector’s efficacy
and safety with only one strain of mice and be
aware that confounding data could occur if differ-
ent genetic backgrounds of a disease model have
been used by different studies. Therefore, it is our
suggestion that preclinical evaluation of AAV-
based vectors should involve the disease models in
multiple genetic backgrounds when possible.
MATERIALS AND METHODS
Plasmid construction and rAAV production
The plasmid construction and rAAV production
are performed by the UNC vector core. For pack-
aging of rAAV vectors, the classical three-plasmid-
based production method was used.21 Briefly, 293
cells were cotransfected with three plasmids con-
sisting of an AAV helper plasmid (AAV2 Rep and
the AAV Cap from serotypes AAV2, 5, 7, 8, or 9), a
vector plasmid containing the ITRs from AAV2
flanking an EGFP transgene driven by the CBh
promoter, and an adenoviral helper plasmid. Cells
were harvested 72 h post-transfection and collected
by centrifugation. Purification was performed us-
ing iodixanol gradient ultracentrifugation and
further purified by column chromatography. Final
preparations were dialyzed against phosphate-
buffered saline (PBS) and adjusted to 1 · 1012 vg
(viral genome) per milliliter for all the AAV vectors.
Animals and intracerebral viral injection
Six-week-old female C57 BL/6J and FVB/N mice
were purchased from the Jackson Laboratory. For
intracerebral viral injection, continual anesthesia
was induced by isoflurane (1–2%) inhalation. The
head of the mouse was fixed to the stereotaxic ap-
paratus (KOPF Instruments, Tujunga, CA) and a
small hole was made. The coordinates used for in-
trastriatal injection are anterior/posterior +0.9 mm,
medial/lateral -1.5 mm, and dorsal/ventral -3.2 mm
relative to bregma. One microliter of the viral vec-
tor was delivered by Hamilton syringe (5 lL ca-
pacity) driven by a legato 130 syringe pump at a
constant flow rate of 100 nL/min. Each animal re-
ceived a total of 1E9 vg in a 1 lL volume. The needle
(33 gauge) was left in place for a further 7 min be-
fore being removed and the incision was sutured
back together.
Immunostaining
All the viral-injected mice, except the mice used
in the behavior study, were sacrificed 5 weeks after
virus injection. The animals were transcardially
perfused using PBS and 4% paraformaldehyde
(PFA). Brains were dissected and immersed in 4%
PFA overnight. Fixed brains were transferred to
30% sucrose for cryoprotection. The brains were
then cut on a cryostat (Leica CM 3050S) to 40-lm-
thick coronal slices. The slices were kept in a
cryoprotectant reagent and stored at -20. For
immunofluorescent staining, the free floating brain
slices were washed with PBS and then twice with
tris-buffered saline (TBS) containing 0.05% Triton
X-100 (washing buffer). Then the slices were per-
meabilized with TBS containing 0.5% Triton-X 100
for 20 min. After that, the slices were incubated in
blocking buffer (TBS, 3% donkey serum, and 0.5%
Triton X-100) for 1 h at room temperature, and
followed by incubation with primary antibodies in
blocking buffer at 4C overnight. Primary anti-
bodies were used as follows: NeuN (mouse; Milli-
pore/Sigma #MAB377; dilution 1:100); GFAP (rat;
Thermo Fisher #13-0300; dilution 1:500); Iba-1
(rabbit; Wako; #019-19741; dilution 1:500); Olig-2
(rabbit; Millipore/Sigma, #AB9610; dilution 1:400);
and DARPP-32 (rabbit; Cell Signal, #2306; dilution
1:400). On the following day, the brain sections
were rinsed three times in washing buffer and
followed by incubation with secondary antibodies
conjugated with the appropriate fluorescent dyes
(Alexa Fluor 488, Alexa Fluor 594, or 647; Jackson
ImmunoResearch) for 2 h at room temperature.
Finally, the sections were rinsed 3 times in wash-
ing buffer, followed by DAPI, 4¢,6-diamidino-
2-phenylindole (DAPI) staining for 15 min, and
mounted onto positively charged glass slides using
antifading mounting media (Thermo Fisher, Pro-
Long gold antifade).
Confocal imaging and data analysis
Coronal sections through the entire striatum
were collected in a serial order. Images were ac-
quired by an Olympus FluoView 3000RS confocal
microscope (Olympus Corporation, Tokyo, Japan)
with 2 · /0.08 (magnification/N.A.), 20 · /0.75, or
30 · /1.05 (silicone oil) objectives in the UNC
Neuroscience Center Microscopy Core facility.
Tiled images with z-stacks (1.5-lm intervals) were
acquired and stitched using Olympus FluoView
software. ImageJ (http://rsbweb.nih.gov/ij/) or
Imaris (Bitplane) software was used for quantifi-
cation. For fluorescence index calculations, the
five serial slices (240-lm-thick sections) with the
highest viral EGFP expression were identified and
the EGFP expression level was quantified. The
fluorescence index was calculated as the sum
EGFP signal intensity of all of the pixels deter-
mined to have a positive signal (thresholded above
background level expression determined from the
average of three nonexpressing regions within the
same image). The single slice with the highest viral
EGFP expression was chosen to be a representative
of each animal. Diffusion volumes were quantified
using the volume of positive EGFP signals (deter-
mined to be above the background level threshold)
from five serial slices with the highest EGFP ex-
pression levels. Colocalization was quantified with
Imaris software using Spot segmentation on the
DAPI signal, in an imaging size of 826.156 ·
829.47 · 10.5 lm. The percentage of cells positive
for a specific marker was calculated as the total
number of specific marker-positive neurons that
colocalized with EGFP expressing neurons divided
by the total number of EGFP expressing neurons.
The NeuN-positive cell numbers were quantified
in the ipsilateral half hemisphere of the brain, and
the microglial fluorescence index was calculated
in the striatum region.
Accelerating rotarod test
AAV7-injected FVB mice and untreated FVB
mice were subjected to behavior testing of acceler-
ating rotarod in the UNC behavior core facility.
Mice were placed on a cylinder that slowly accel-
erated to a constant rotating speed. For each trial,
revolutions per minute (rpm) are set at an initial
value of 3, with a progressive increase to a maxi-
mum of 30 rpm across 5 min, the maximum trial
length. The mice were first trained using three
trials, with 45 s between each trial. Then, the mice
were evaluated with two trials for their motor
performance. Measures are taken of the latency for
the mouse to fall from the top of the rotating barrel.
Statistics
All statistical analyses were performed using
GraphPad software. For the behavioral testing
animal, NeuN cell density, intact NeuN area per-
centage, and rotarod test were performed using
unpaired two-tailed Student’s t-tests. For all the
other statistics, two-way ANOVA followed by
multiple comparisons was used.
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